CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-01). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 1925 · Search date 2026-08-01 · Methodology v0.6

Bright light therapy,
does it really help with Improved depressive symptoms and remission in winter seasonal affective disorder?

30-Second Summary
C
Evidence Grade C · 55 · Safety caution
Illuminance is measurable, but efficacy evidence is limited by a failed mean-score comparison and small short trials
Headache, glare or eye strain, agitation, and insomnia can occur. People with bipolar disorder, retinal disease, or photosensitizing medication should seek professional guidance.
What the
research shows
The grade is C. Eastman randomized 121 people, but only 96 completed and 25 (20.7%) dropped out. Mean SIGH-SAD scores did not differ across groups, while strict remission was 61% with morning light, 50% with evening light, and 32% with negative-ion placebo. A 21-trial symptom synthesis found Hedges' g -0.38, but difficult blinding, subjective symptom assessment, and substantial attrition give C with 55 points.
What the
ads claim
A large lux number does not by itself establish antidepressant efficacy. Products should specify lux at eye position, distance, and duration, and should separate mean symptom scores from remission rates.
*

Useful facts when choosing a product

  • The Eastman light boxes delivered about 6,000 lux at eye position for 1.5 hours daily over four weeks.
  • Illuminance changes with distance and angle, so a lamp-face rating alone does not establish eye-level exposure.
  • The measured output is separate from clinical efficacy; mean depression scores did not differ in the same trial.
Gap Measurement · Verdict 1925 · C 55
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Eastman randomized 121 people but analyzed 96 completers: 33 morning light, 32 evening light, and 31 negative-ion placebo. Twenty-five participants dropped out, or 20.7%. Raters were blinded to equipment and timing, but participants could see bright-light exposure, making intervention blinding inherently difficult; the key depression outcome depended on participant-reported symptoms captured in a structured rating interview. Controls were not no treatment: they included a negative-ion sham and bright light at another time, while related trials used low-dose light or negative-ion controls. Mean scores were null and the morning-light versus negative-ion strict-remission contrast was positive.

02

Why this is classified as C (55)

Remission and pooled symptom signals were positive, but bright light is difficult to blind, the key symptom outcome is subjective, and 25 of 121 participants (20.7%) dropped out, alongside small short trials, giving C with 55 points.

Counterpoint. A treatment signal exists, but magnitude, optimal schedule, and durability remain uncertain.

Rejudgment record. Cross-check applied — The pivotal mean symptom comparison failed, while strict remission and small-trial synthesis were positive but limited by completer, short-duration, and abstract-only reporting

Scoring profile behind this grade
EndpointPPatient-reported treatment goal - the symptom is the goal
ReplicationR2Independently replicated across trials
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (C).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Improved mean SIGH-SAD score at four weeksDEastman found no difference in mean scores among the three groups.
Increased strict remission at four weeksCMorning light achieved 61% versus 32% with negative-ion placebo, but this was a completer analysis.
Pooled symptom improvement in seasonal affective disorderCHedges' g was -0.38 across 21 trials, but the synthesis was reported only as a conference abstract.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Three-arm randomized placebo-controlled four-week trial with blinded raters25U.S. National Institute of Mental HealthWeekly mean SIGH-SAD score and strict remissionNo group difference in mean scores at four weeks; strict remission 61% morning light, 50% evening light, 32% placebo; morning light versus placebo P<0.05Pivotal but limited by null mean scores and a completer analysis after 20.7% attrition
Study 2Systematic search and meta-analysis of randomized placebo-controlled trials reported as a conference abstract12Academic analysis; funding of all included trials was not fully reported in the abstractChange on validated depression scales and response rateSymptoms Hedges' g -0.38 (95% CI -0.53 to -0.23), P=0.0001; response RR 1.31 (95% CI 1.01 to 1.69), P=0.04Positive pooled signal but abstract-only reporting
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-08-01).

Eastman CI, Young MA, Fogg LF, Liu L, Meaden PM. Bright Light Treatment of Winter Depression: A Placebo-Controlled Trial. Arch Gen Psychiatry. 1998;55:883-889. DOI: 10.1001/archpsyc.55.10.883.
checked
Friedrich ME, Cambioli L, Dold M, et al. PS226. The efficacy of light therapy in the treatment of seasonal affective disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2016;19(Suppl 1):82-83. DOI: 10.1093/ijnp/pyw043.226.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-01 · Corrections: none

Cite this verdict

Bright light therapy x symptoms and remission in seasonal affective disorder Evidence Grade C card
[Chamgap] Bright light therapy x symptoms and remission in seasonal affective disorder — Evidence Grade C·55. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/mood/bright-light-therapy-seasonal-affective-disorder-symptoms-remission/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.